Sanofi gets CDSCO panel marketing authorization for Insulin Glargine
New Delhi: Approving the waiver of additional requirements for local clinical trials in the country, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization to Sanofi Healthcare India for the Insulin Glargine 100 IU/mL cartridge.
This came in the wake of the proposal presented by Sanofi Healthcare India for marketing authorization for the Insulin Glargine 100 IU/mL cartridge with a request for a waiver for additional requirements for local clinical trials.
This manufacturing of the drug product will be held at an additional site in the country using drug substances imported from Frankfurt, Germany.
Insulin glargine is a modified form of long-acting or basal insulin used to control hyperglycemia in diabetes mellitus. Insulin glargine is produced by recombinant DNA technology utilising Escherichia coli (K12 strain) as the production organism.
Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesise the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glargine, to lower glucose levels in the blood.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.